BACKGROUND: Patient-centered research requires the meaningful involvement of patients and caregivers throughout the research process. The objective of this study was to create a process for sustainable engagement for research prioritization within oncology. METHODS: From December 2014 to 2016, a network of engaged patients for research prioritization was created in partnership with the Bladder Cancer Advocacy Network (BCAN): the BCAN Patient Survey Network (PSN). The PSN leveraged an online bladder cancer community with additional recruitment through print advertisements and social media campaigns. Prioritized research questions were developed through a modified Delphi process and were iterated through multidisciplinary working groups and a repeat survey. RESULTS: In year 1 of the PSN, 354 patients and caregivers responded to the research prioritization survey; the number of responses increased to 1034 in year 2. The majority of respondents had non-muscle-invasive bladder cancer (NMIBC), and the mean time since diagnosis was 5 years. Stakeholder-identified questions for noninvasive, invasive, and metastatic disease were prioritized by the PSN. Free-text questions were sorted with thematic mapping. Several questions submitted by respondents were among the prioritized research questions. A final prioritized list of research questions was disseminated to various funding agencies, and a highly ranked NMIBC research question was included as a priority area in the 2017 Patient-Centered Outcomes Research Institute announcement of pragmatic trial funding. CONCLUSIONS: Patient engagement is needed to identify high-priority research questions in oncology.
INTRODUCTION
Successful patient-centered research requires the meaningful involvement of patients and caregivers throughout the research process; this is also known as patient engagement. Engagement is required by the Patient-Centered Outcomes Research Institute (PCORI), which has a mandate for stakeholder participation in all aspects of research, spanning research prioritization to dissemination and implementation. Understanding topic prioritization and selection is arguably the most important aspect of the research timeline to avoid unnecessary costs and ensure the maximum impact of research dollars. Patient and other stakeholder participation can help researchers ensure the relevance of research questions, design patient-centered study protocols, select relevant outcomes, facilitate recruitment, and improve dissemination and implementation.
Traditionally, groups of scientists have independently identified priorities despite areas of research in which patient viewpoints have relevance. Through PCORI and other patient advocacy organizations, there has been increasing recognition that patients and caregivers offer valuable contributions that have the potential to shape research agendas and funding. Through the involvement of patient stakeholders, previously unrecognized topics and issues have emerged in a variety of settings ranging from Alzheimer disease 1 to asthma 2 and arthritis. 3, 4 Interestingly, the questions posed by patients and clinicians were not aligned with those that had been prioritized by funding agencies. A recent study looked at more than 300 studies and identified only 6 that compared patient priorities with those of researchers.
Research prioritization in oncology has largely relied on multistakeholder panels that achieve consensus with modified Delphi approaches. 6 However, a large-scale understanding of research prioritization in the broader patient community is challenging. Building large patient databases for diversity in perspective and experience remains a challenge. High-tech engagement approaches conducted online have recently garnered more support 7 because these approaches are scalable, offer convenience to the patient, and can facilitate the engagement of a larger number of stakeholders at lower cost. A larger group of engaged patients further allows stratification of responses and better aligned priorities within subsets of a disease. However, successful examples of these databases are limited. Herein, we describe our process of online engagement with the Bladder Cancer Advocacy Network (BCAN) Patient Survey Network (PSN). The results from the BCAN PSN illustrate the potential contribution of patient engagement to research prioritization and the identification of patient-centered research topics in oncology.
MATERIALS AND METHODS
From December 2014 to December 2016, a partnership was established between the BCAN and 2 investigators (A.S. and J.G.) to create a network of engaged patients for research prioritization in bladder cancer. Supported by a PCORI Engagement Award, the BCAN PSN was created to facilitate research prioritization with a multistep methodology as described later in this article. This work was exempt from the University of North Carolina Institutional Review Board.
Establishing the BCAN PSN
The initial establishment of the BCAN PSN leveraged the existing BCAN Inspire online community. An e-mail soliciting enrollment in the PSN was sent to Inspire BCAN community members, with an additional online promotion encouraging patients with bladder cancer and/ or their caregivers to join. We continued to build off the BCAN PSN with advertisements targeting community and academic urologists, the patient-driven survivor-tosurvivor program through BCAN, online and print advertisements sent to bladder cancer support groups and treatment centers, and social media campaigns through blogs, webinars, and Twitter. We attempted to increase diversity by targeting underrepresented groups, including black and Hispanic patients with bladder cancer and their caregivers. Once participants joined the BCAN PSN, they signed a disclaimer allowing us to enter them into a database housed through REDCap in Nashville, Tennessee (a Health Insurance Portability and Accountability Actcompliant secure Web application that allows survey building while maintaining confidentiality). Patient participants were asked to report their current age, age at diagnosis, sex, race/ethnicity, state of residence, highest level of education, household income, histology (if known), disease stage (if known), treatment received (including intravesical treatment, systemic chemotherapy, surgery, and radiation), and date of last treatment. Caregiver participants were asked to report their age, sex, race/ ethnicity, state of residence, household income, highest level of education, and questions regarding their loved ones' disease stage, treatment, and histology (if known). Socioeconomic questions were not included in year 1 of the BCAN PSN, but they were included in year 2 at the suggestion of our multistakeholder advisory panel.
All participants were asked to include their e-mail address for future correspondence for ongoing research prioritization efforts and related contact for research opportunities. The recruitment e-mail was sent 5 times, with the messages spaced 1 to 2 weeks apart, as a reminder to complete the survey. To be inclusive of patients without Internet access, we provided a phone number as well as the option to mail responses. Because of the multimodal approach undertaken for recruitment, we were unable to calculate an accurate response rate for the PSN.
Survey Development
To generate an initial list of bladder cancer research questions, we used a modified Delphi method to survey participants of the annual BCAN Think Tank. The BCAN Think Tank is a 200-person advocacy meeting held each year in which a variety of stakeholders come together to discuss contemporary issues in bladder cancer research. First, we surveyed participants regarding which research questions would be relevant to patients with bladder cancer. We then compiled these questions and sent a second survey asking them to rank these questions in order of importance. The finalized list was then discussed in a multistakeholder BCAN working group. The multistakeholder BCAN group included patients and patient advocates affected by bladder cancer, urologists, medical oncologists, radiation oncologists, nurses, a social worker, a representative from a funding agency (the National Cancer Institute), and representatives from industry. The top 3 questions for each disease stage (non-muscle-invasive bladder cancer [NMIBC], muscle-invasive bladder cancer [MIBC] , and metastatic bladder cancer) emerged from this discussion and would be used to survey the larger BCAN PSN. The final questions derived from the Delphi Cancer process with the multistakeholder BCAN group were reviewed by the patient stakeholders to clarify language and readability before round 1 of the BCAN PSN.
During year 2 of the PSN, we reconvened our multistakeholder working group. The first day was dedicated to describing and discussing the year 1 results. The second day involved the stratification and selection of questions for BCAN PSN prioritization. Through discussion and feedback from panel members, several changes arose. First, more than 3 questions emerged from each disease stage. Second, additional questions derived from the year 1 BCAN PSN were added. Third, the final set of questions for each disease stage would be designated only for those patients identifying with that stage. The finalized list was iterated with patient and caregiver advocates to ensure that the language was patient-centered. This list was again distributed to the multistakeholder BCAN working group for comment and revision. During year 2, the final questions for each disease stage included 5 questions for NMIBC, 4 questions for MIBC, and 4 questions for metastatic bladder cancer.
Survey Administration
Top-ranked research questions were sent to participants of the BCAN PSN and advertised to additional patients and caregivers through the BCAN Web site, print, and social media. The survey asked participants to rank order research questions in specific stage groupings. Participants were also permitted to submit their own research questions with free-text response options. Year 1 survey administration was performed through REDCap; to facilitate skip logic and the availability of a Spanish translation, year 2 survey administration was performed through Qualtrics (Provo, Utah). The survey was translated into Spanish and backtranslated into English to ensure accuracy. Responses were linked with data from each user to stratify results on the basis of disease stage, sex, and other demographic variables. During year 2, the survey was sent every 1 to 2 weeks as a reminder for approximately 1.5 months; this ended in the final week of Bladder Health Awareness Month in November.
Obtaining Consensus on Research Prioritization
All data were compiled and free-text responses sorted with thematic analysis. We organized responses by bladder cancer stage or type of cancer treatment. Our multistakeholder working group conducted an online discussion of prioritized research questions, including additional prioritized free-text research questions submitted by BCAN PSN participants, and we assembled a ranked list of priority topics/questions. We emphasized comparative effectiveness research (CER) questions with the aim of providing PCORI with a specific list of bladder cancer CER topics of importance to patients, caregivers, and the multistakeholder working group. The final ranked list of bladder cancer research questions was delivered to funding agencies to assist with grant review, including the Agency for Healthcare Research and Quality, PCORI, and the National Cancer Institute.
RESULTS
During year 1 of the BCAN PSN, 781 patients and caregivers enrolled, and 354 responded to the research prioritization survey. The survey response count increased to 1034 in year 2. Demographics during years 1 and 2 were similar (Table 1) ; most patients were men and were white. Respondents were of similar ages in year 1 and year 2. Most respondents had NMIBC, and this was consistent with observed bladder cancer epidemiology in the United States. 8 In year 2, respondents reported mean times of 5 years since diagnosis and 2.5 years since treatment.
In year 1, the multistakeholder working group submitted and ranked 30, 20, and 25 research questions for NMIBC, MIBC, and metastatic bladder cancer, respectively. The top 10 questions for each stage category were discussed, and the top 3 questions in each stage category were selected for the BCAN PSN survey. Prioritized questions were supplemented with additional free-text questions submitted for NMIBC (n 5 82), MIBC (n 5 32), and metastatic bladder cancer (n 5 8). These were sorted into common themes, including the following for NMIBC among others: 1) the role of complementary medicine and nutrition in bladder cancer treatment, 2) the efficacy of different medication dosages, 3) appropriate durations of treatment, and 4) appropriate follow-up schedules for intravesical therapy. We constructed a final prioritized list of research questions, which was disseminated to a variety of funding agencies, including PCORI, the National Cancer Institute, and the Agency for Healthcare Research and Quality (Fig. 1) .
In year 2, we used the year 1 questions and incorporated submitted suggestions to improve the year 1 survey administration and streamline the methodology for future research prioritization iterations; we paid attention to increasing the diversity of the BCAN PSN and limiting respondents to prioritization within their own disease stage category. From our year 2 multistakeholder working group, we included 5 questions for NMIBC, 4 questions for MIBC, and 4 questions for metastatic bladder cancer in the year 2 BCAN PSN.
Cancer
Prioritization rankings for each question are stratified by disease stage category in Figure 2A -C. Prioritization rankings did not differ by patient or caregiver status (Supporting Figs. 2-4) , although a slightly higher percentage of caregivers prioritized bladder removal decision making for NMIBC and the evaluation of the caregiver burden for metastatic disease. To assess whether research priorities changed with the time since treatment, we stratified responses among those less than and at least 5 years from treatment, and our results did not differ (Supporting Tables 1-3 ). Most respondents (96%) felt that the final research questions in the BCAN PSN survey were important to patients with bladder cancer (Supporting Table 4 ). Additional free-text questions were submitted for NMIBC (n 5 187), MIBC (n 5 91), and metastatic bladder cancer (n 5 1), and these were sorted into themes. Based on these themes, several questions were added to the BCAN PSN, including 1) the impact of lifestyle and dietary interventions on bladder cancer management, 2) a comparison of protocols for NMIBC unresponsive to bacille Calmette-Gu erin, 3) best practices for selecting a physician/hospital, and 4) a comparison of the best time to start hospice care. The final list of prioritized questions stratified by bladder cancer stage is displayed in Figure 3 .
DISCUSSION
Patient engagement in research prioritization is critical to the allocation of resources to research questions with high patient value. Through partnership with a bladder cancer advocacy organization (BCAN), we were able to create a sustainable method for online research prioritization to inform funding agencies of those research questions with the highest impact for patients. Emphasizing patientcentered research focuses investigators' efforts by ensuring the relevancy of research topics, but it also sets the groundwork for several phases of engagement. Engagement phases can be organized into 3 categories: they begin with a preparatory phase and end with execution and translational phases. 9 The preparatory phase can be further divided into 2 stages: agenda setting and funding. Our project focused primarily on this initial phase, which is gaining traction in the research community. In a systematic review describing the current state of patient engagement in research, 33 of 202 studies included engagement within this phase and broadly demonstrated its importance in shaping research priorities. 9 Among 156 studies addressing research prioritization, 148 demonstrated successful identification of important research topics. The majority of these studies addressed nononcologic topics but provided evidence of effectiveness that can be translated to cancer research.
We demonstrated the feasibility of creating a sustainable platform for research priority setting in bladder cancer that can be easily applied to other malignancies Figure 2 . Rank order prioritization of (A) non-muscle-invasive bladder cancer, (B) muscle-invasive bladder cancer, and (C) metastatic bladder cancer research questions. The rank order reflects the proportion of respondents who selected that question as first through fifth in the priority rating. BCG indicates bacille Calmette-Gu erin.
through partnerships with advocacy organizations and online patient forums. We benefited from the large patient population that frequents the online BCAN forums for social support and clinical questions. However, if a cancer site has more than 1 advocacy organization, a patient survey network could apply snowballing to reach larger patient populations through either support organizations or clinical networks. The 2-stage prioritization methodology uses a modified Delphi process to ensure input from all respondents and enables submitted research questions to ascend prioritization rankings.
Despite our success, we identified several challenges that will inform future engagement efforts. First, the language used in communications and surveys required iterations to minimize stakeholder confusion and discomfort.
Second, we needed to clarify the differences between research conduct and research prioritization, which we overcame through formal presentations, webinars, and social media. Third, patients initially felt uncomfortable attending stakeholder meetings with researcher and clinician stakeholders. Creating an environment that placed value on the patient perspective and involved patients from inception was critical for the success of the BCAN PSN. Patients assisted with the design of the BCAN PSN logo (Supporting Fig. 1 ) as well as the structure of the BCAN PSN survey. Fourth, the mechanism by which patients enunciate research questions may differ from researcher processes. During the generation of research ideas, patients often outlined clinical questions through storytelling. For example, a patient who experienced Cancer discomfort from surveillance cystoscopies found that different comfort techniques were used with different urologists. From this story, we created the following research question: What is the comparative effectiveness of various methods of reducing cystoscopy discomfort? Fifth, some patient-generated research ideas included topics that had already been studied, did not represent CER, or were not feasible. Ensuring a multistakeholder research group allowed a more robust discussion to focus our efforts. For example, patient-proposed research topics that did not align with CER would be gently redirected by researchers. Similarly, researcher-proposed topics and designs (eg, randomization versus prospective studies) would be gently redirected by patients who would speak of feasibility from a patient perspective.
Another challenge encountered was ensuring diverse representation within the BCAN PSN with a high-tech approach. Diverse representation should ideally include all patient populations, including those who are hard to reach. Hard-to-reach patient populations include those with low literacy, barriers to using the Internet, numerous work/family obligations, and other barriers that preclude the time and resources to participate in online surveys. Priorities expressed by these hard-to-reach patient populations (eg, Internet barriers and low literacy) may differ from those expressed by the current PSN. Although we targeted increased racial and ethnic diversity for year 2 and we applied several methods to improve engagement among minority groups, 10 diversity in the BCAN PSN was lacking. We directed advertisements to health systems and support groups with higher percentages of minority groups and approached the affiliated providers. We also included survey items to better understand socioeconomic status within the BCAN PSN on the basis of recommendations from patient stakeholders within our multistakeholder working group; however, some respondents disapproved of these questions. The survey item was included, but we made responses optional as a compromise. After year 2 of the BCAN PSN, the multistakeholder BCAN panel reconvened to discuss strategies for improving the diversity of BCAN PSN respondents. Future changes to the BCAN PSN will include the incorporation of research questions derived from communications through a BCAN telephone helpline, which may increase the representation of perspectives of non-Internet users, and point-of-care BCAN PSN research question generation and prioritization.
Despite these challenges, our project had several strengths. Importantly, we conducted 2 rounds of survey administration to allow submitted questions to be prioritized, and we provided the results to the BCAN PSN respondents for comment before dissemination. We defined success as the dissemination of ranked priority questions. Importantly, research related to topic prioritization among funding agencies has been limited. 9 A 2007 survey of 32 organizations revealed that only 20% considered patient-prioritized research lists in funding decisions.
11 Current funding decisions are largely based on the judgment of scientific merit rather than the relevance of anticipated study outcomes to patients affected by the disease. Through the BCAN PSN, we were able to provide a list of prioritized research topics to various funding agencies. Although the full impact of this may not be realized for several years, 1 highly ranked NMIBC research question from 2016 was included as a priority area in the 2017 PCORI announcement of pragmatic trial funding.
Although our project focused on the initial preparation phase of engagement, we recognize the importance of the other phases of engagement: execution and translation. Patient engagement in the execution phase includes study design, recruitment and participation in data collection, and analysis of study results. Engaged patients can raise ethical considerations for trial design, identify barriers and solutions for low trial enrollment, highlight important patient-reported outcomes for inclusion in the study design, identify other relevant outcomes, and contextualize conclusions from study analyses, adding cultural insight and patient-centered interpretations. Within the translation phase, patients can assist with the dissemination of results through media, patient education, and support networks. 9 Our future work will focus on expanding and enhancing the BCAN PSN. More than 95% of BCAN PSN members expressed interest in future research engagement. However, most members lack formal research training. Toward that end, we plan to develop a bladder cancer research training module supplemented with existing training materials available through the Initiative to Support Patient Involvement in Research (INSPIRE), which is a PCORI-funded, Web-based portal. 12 The effectiveness of this patient-centered research training tool will be tested through the development of a research study focusing on a CER question prioritized by the BCAN PSN. By engaging and enabling patients with bladder cancer to become more involved in the research process, we will foster effective patient-centered outcomes research partnerships between patients, clinicians, and researchers.
In conclusion, we developed and implemented a bladder cancer-specific survey network that produced a list of prioritized research questions stratified by bladder cancer stage, which led to a bladder cancer-specific funding opportunity. The BCAN PSN has provided an opportunity for increased patient-researcher engagement beyond research prioritization, including input on the design of bladder cancer trials. The methods reported herein can be extrapolated to other malignancies to ensure incorporation of the patient voice into oncologic research from the conception of the research question through the dissemination and implementation of study findings.
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